The effect of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (paf-acether) on the arterial wall

R BourgainM Braquet


The effect of a topical paf-acether superfusion over an injured arterial segment was assessed in the guinea-pig, using an opto-electronic in vivo thrombosis model allowing on-line quantification of small platelet thrombus dynamics. As compared to control, ADP-induced, thromboformation and behaviour, exogenous paf-acether causes a large, dense platelet thrombus, invaded and surrounded by numerous leukocytes, spreading widely over the adjoining, vacuolized, endothelium. Its embolization has to be forced with prostanoids, mepacrine, EDTA, or with a specific paf-acether antagonist (BN 52021). A few minutes after such forced embolization, a new thrombus starts growing at the same site, without renewal of the paf-acether superfusion. This phenomenon of spontaneous reappearance after forced embolization can be followed during several hours. Experiments with labelled paf-acether and the paf-acether antagonist indicate a possible endogenous paf-acether (or paf-acether-like) production triggered by superfusion with exogenous paf-acether.


Apr 1, 1974·Thrombosis Research·R H Bourgain, F Six
Jun 1, 1984·Naunyn-Schmiedeberg's Archives of Pharmacology·A M LeferJ B Smith
Jan 21, 1983·European Journal of Pharmacology·P BessinJ Benveniste
Apr 1, 1984·Canadian Journal of Physiology and Pharmacology·Y KasuyaK Shigenobu
Jun 1, 1983·Inflammation·C M Suquet, R W Leid
Jan 1, 1981·Annals of the New York Academy of Sciences·B B VargaftigF Wal
Mar 16, 1981·Biochemical and Biophysical Research Communications·D J HanahanR N Pinckard
Sep 1, 1981·Inflammation·J T O'FlahertyL R DeChatelet

❮ Previous
Next ❯


Aug 1, 1991·Annals of Neurology·P J LindsbergG Feuerstein
Feb 1, 1988·Digestive Diseases and Sciences·J L Wallace, B J Whittle
Dec 1, 1991·Lipids·R RabinoviciG Feuerstein
Jun 10, 1988·European Journal of Pharmacology·J LefortB B Vargaftig
Jan 1, 1989·Pharmacology & Therapeutics·J MorleyI Chapman
Jan 1, 1989·Trends in Pharmacological Sciences·P BraquetD Hosford
Jan 1, 1987·Immunology Today·P Braquet, M Rola-Pleszcynski
Jan 1, 1996·Journal of Lipid Mediators and Cell Signalling·J SugataniS Ito
Feb 1, 1988·Burns, Including Thermal Injury·P LavaudR Ducousso
Apr 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·A G StewartG J Dusting
Jan 1, 1997·Journal of Basic and Clinical Physiology and Pharmacology·C KüçükhüseyinA Barlas
Oct 1, 1996·The Journal of Trauma·F M Abu-ZidanS Lennquist
Aug 1, 1986·Pharmacological Research Communications·L MaesP Braquet
Jan 1, 1994·Prostaglandins, Leukotrienes, and Essential Fatty Acids·A M Evangelou
Oct 1, 1987·British Journal of Pharmacology·E CoëffierB B Vargaftig
Jan 1, 1989·Annals of the New York Academy of Sciences·P BraquetN G Bazan
Sep 1, 1987·Circulation Research·G Y Grigorian, U S Ryan
May 1, 1989·Stroke; a Journal of Cerebral Circulation·R JosephG D'Andrea
May 1, 1997·Arteriosclerosis, Thrombosis, and Vascular Biology·J FrostegårdL Schäfer-Elinder
Oct 1, 1990·Stroke; a Journal of Cerebral Circulation·P J LindsbergG Feuerstein
Oct 7, 1998·Circulation·J W Kinn, R J Bache
Oct 4, 2000·Physiological Reviews·G MontrucchioG Camussi
May 1, 1989·Biochemical Pharmacology·M PretolaniB B Vargaftig

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.